子宫内膜癌的个体化治疗：挑战与机遇。
Personalized therapy in endometrial cancer: challenges and opportunities.
机构信息
Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Cancer Biol Ther. 2012 Jan 1;13(1):1-13. doi: 10.4161/cbt.13.1.18438.
Abstract
Early stage endometrial cancer is generally curable. However, progress in the treatment of advanced and recurrent endometrial cancer has been limited. This has led to a shift from the use of traditional chemotherapeutic agents and radiotherapy regimens to the promising area of targeted therapy, given the large number of druggable molecular alterations found in endometrial cancer. To maximize the effects of directed targeted therapy, careful molecular characterization of the endometrial tumor is necessary. This represents an important difference in the use of targeted therapy vs. traditional chemotherapy or radiation treatment. This review will discuss relevant pathways to target in endometrial cancer as well as the challenges that arise during development of a personalized oncology approach.
摘要
早期子宫内膜癌通常是可治愈的。然而，晚期和复发性子宫内膜癌的治疗进展有限。鉴于在子宫内膜癌中发现了大量可用药的分子改变，这促使人们从传统的化疗药物和放疗方案转向有前途的靶向治疗领域。为了最大限度地提高靶向治疗的效果，有必要对子宫内膜肿瘤进行仔细的分子特征分析。这是靶向治疗与传统化疗或放疗相比的一个重要区别。本文将讨论在子宫内膜癌中靶向相关途径以及在制定个性化肿瘤学方法时出现的挑战。
相似文献
1
Personalized therapy in endometrial cancer: challenges and opportunities.子宫内膜癌的个体化治疗：挑战与机遇。
Cancer Biol Ther. 2012 Jan 1;13(1):1-13. doi: 10.4161/cbt.13.1.18438.
2
Adjuvant chemotherapy for advanced endometrial cancer.晚期子宫内膜癌的辅助化疗。
Cochrane Database Syst Rev. 2014 May 15;2014(5):CD010681. doi: 10.1002/14651858.CD010681.pub2.
3
What's new in systemic therapy for endometrial cancer.子宫内膜癌全身治疗的新进展。
Curr Opin Oncol. 2005 Sep;17(5):500-4. doi: 10.1097/01.cco.0000174165.99109.77.
4
Update on the chemotherapeutic management of endometrial cancer.子宫内膜癌化疗管理的最新进展。
Clin Adv Hematol Oncol. 2014 Oct;12(10):659-65.
5
Adjuvant treatment of advanced-stage endometrial cancer.晚期子宫内膜癌的辅助治疗。
Clin Obstet Gynecol. 2011 Jun;54(2):256-65. doi: 10.1097/GRF.0b013e318218c659.
6
Systemic therapy for the treatment of endometrial cancer.子宫内膜癌的系统治疗。
Expert Opin Pharmacother. 2019 Nov;20(16):2019-2032. doi: 10.1080/14656566.2019.1654996. Epub 2019 Aug 26.
7
Systemic therapy for recurrent endometrial cancer: a review of North American trials.复发性子宫内膜癌的全身治疗：北美试验综述
Expert Rev Anticancer Ther. 2009 Jul;9(7):905-16. doi: 10.1586/era.09.54.
8
An update on the current pharmacotherapy for endometrial cancer.子宫内膜癌当前药物治疗的最新进展。
Expert Opin Pharmacother. 2016;17(4):489-99. doi: 10.1517/14656566.2016.1127351. Epub 2015 Dec 23.
9
Management of advanced-stage and recurrent endometrial cancer.晚期及复发性子宫内膜癌的管理
Semin Oncol. 2009 Apr;36(2):145-54. doi: 10.1053/j.seminoncol.2008.12.006.
10
Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.子宫内膜癌的辅助化疗：随机试验综述
Clin Oncol (R Coll Radiol). 2008 Aug;20(6):463-9. doi: 10.1016/j.clon.2008.04.001. Epub 2008 May 7.
引用本文的文献
1
Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy.子宫内膜癌的新型分子靶点：治疗机制与前景
Biologics. 2024 Mar 21;18:79-93. doi: 10.2147/BTT.S369783. eCollection 2024.
2
Mechanism of regulation of KIF23 on endometrial cancer cell growth and apoptosis.KIF23对子宫内膜癌细胞生长和凋亡的调控机制。
Discov Oncol. 2024 Mar 21;15(1):83. doi: 10.1007/s12672-024-00937-x.
3
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.在子宫内膜癌中使用来曲唑/阿贝西利/LY3023414联合阻断芳香化酶、CDK4/6和PI3K
Gynecol Oncol Rep. 2024 Feb 22;52:101348. doi: 10.1016/j.gore.2024.101348. eCollection 2024 Apr.
4
Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer.全外显子组测序揭示了子宫内膜癌患者腹水中循环肿瘤DNA和血浆中循环肿瘤DNA的临床潜力。
Cancers (Basel). 2022 May 19;14(10):2506. doi: 10.3390/cancers14102506.
5
Metformin Intervention-A Panacea for Cancer Treatment?二甲双胍干预——癌症治疗的万灵药？
Cancers (Basel). 2022 Mar 4;14(5):1336. doi: 10.3390/cancers14051336.
6
Differential Receptor Tyrosine Kinase Phosphorylation in the Uterus of Rats Following Developmental Exposure to Tetrabromobisphenol A.发育过程中暴露于四溴双酚A的大鼠子宫中受体酪氨酸激酶的磷酸化差异
Toxicol Res Appl. 2021 Jan-Dec;5. doi: 10.1177/23978473211047164. Epub 2021 Nov 18.
7
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?子宫内膜癌的分子特征：识别高危患者及制定临床决策指南的关键？
Cancers (Basel). 2021 Aug 7;13(16):3988. doi: 10.3390/cancers13163988.
8
Determinants of Sensitivity to Radiotherapy in Endometrial Cancer.子宫内膜癌放疗敏感性的决定因素
Cancers (Basel). 2020 Jul 15;12(7):1906. doi: 10.3390/cancers12071906.
9
Amniotic epithelial cells reverse abnormal vascular structure and function in endometrial carcinoma.羊膜上皮细胞可逆转子宫内膜癌中异常的血管结构和功能。
Int J Clin Exp Pathol. 2019 Jul 1;12(7):2405-2424. eCollection 2019.
10
Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy.基于磁共振波谱技术的宫颈阴道分泌物代谢组学生物标志物检测子宫内膜癌
Metabolomics. 2019 Oct 29;15(11):146. doi: 10.1007/s11306-019-1609-z.
本文引用的文献
1
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.依维莫司和来曲唑治疗复发性子宫内膜癌的 II 期研究。
J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.
2
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.基于基因突变为转移性黑色素瘤患者分层的 Selumetinib（AZD6244；ARY-142886）联合治疗的临床反应。
Cancer. 2013 Feb 15;119(4):799-805. doi: 10.1002/cncr.27790. Epub 2012 Sep 12.
3
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.Temsirolimus 治疗复发性或转移性子宫内膜癌的 II 期临床研究：NCIC 临床试验组的一项试验。
J Clin Oncol. 2011 Aug 20;29(24):3278-85. doi: 10.1200/JCO.2010.34.1578. Epub 2011 Jul 25.
4
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据，2011 年：消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
5
Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.成纤维细胞生长因子受体是头颈部鳞状细胞癌细胞自分泌信号网络的组成部分。
Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.
6
Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.PI3K 通路抑制在癌症中的现状和未来：前景与局限。
Curr Med Chem. 2011;18(18):2674-85. doi: 10.2174/092986711796011193.
7
Metformin as an antitumor agent in cancer prevention and treatment.二甲双胍作为一种抗肿瘤药物在癌症的预防和治疗中的应用。
J Diabetes. 2011 Dec;3(4):320-7. doi: 10.1111/j.1753-0407.2011.00119.x.
8
Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer.克服耐药性：靶向内分泌难治性乳腺癌中的PI3K/mTOR通路
Cancer Biol Ther. 2011 Jun 1;11(11):947-9. doi: 10.4161/cbt.11.11.15953.
9
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.分子特征可预测临床结局：前瞻性试验将表皮生长因子受体酪氨酸激酶抑制剂吉非替尼的反应与 EGFR 基因酪氨酸结合域的敏化突变的存在相关联。
Clin Cancer Res. 2011 May 15;17(10):3500-6. doi: 10.1158/1078-0432.CCR-10-2102. Epub 2011 May 10.
10
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.贝伐珠单抗治疗复发性或持续性子宫内膜癌的 II 期临床试验：一项妇科肿瘤学组研究。
J Clin Oncol. 2011 Jun 1;29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2.
Zotero 插件